Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy
Status:
Terminated
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess whether certain metabonomics and/or lipidomics
features in correlation with pharmacokinetics before, during and after treatment with
sunitinib or pazopanib in first line can predict toxicity and efficacy of sunitinib or
pazopanib in metastatic clear cell renal cell carcinoma patients.
Phase:
Phase 4
Details
Lead Sponsor:
Cliniques universitaires Saint-Luc- Université Catholique de Louvain Jean-Pascal Machiels